NCT06836492 A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.
| NCT ID | NCT06836492 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Yizhuo Zhang |
| Condition | Rhabdomyosarcoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2017-01-30 |
| Primary Completion | 2029-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 300 participants in total. It began in 2017-01-30 with a primary completion date of 2029-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.
Eligibility Criteria
Inclusion Criteria: 1. 0 years \< age \< 18 years old, regardless of gender; 2. Tumor patients diagnosed by histopathology or bone marrow cytology; 3. Patients are treated for the first time; 4. ECoG score ≤ 2; 5. The expected survival time is more than 8 months; 6. Patient's parent or guardian signs informed consent. Exclusion Criteria: 1. Combined with immunodeficiency disease 2. Second tumor
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06836492 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 18 Years, studying Rhabdomyosarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06836492 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 300 participants.
Is NCT06836492 currently recruiting?
Yes, NCT06836492 is actively recruiting participants. Contact the research team at lusy@sysucc.org.cn for enrollment information.
Where is the NCT06836492 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06836492 clinical trial?
NCT06836492 is sponsored by Yizhuo Zhang. The trial plans to enroll 300 participants.